Departement of Neurology, UZ Leuven
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Damme, Philip van
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Active, not recruiting
3
158
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
NCT05039099 / 2020-005971-11: A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Active, not recruiting
2
63
Europe, Canada, US, RoW
AP-101, Placebo
AL-S Pharma, AL-S Pharma
Amyotrophic Lateral Sclerosis
12/24
10/25
ReALiSe, NCT06441682: A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

Recruiting
2
60
Europe, Canada
ARGX-119, Placebo
argenx
Amyotrophic Lateral Sclerosis
07/27
07/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Damme, Philip van
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Active, not recruiting
3
158
Europe, Canada, Japan, US, RoW
Tofersen, BIIB067, QALSODY, Placebo
Biogen
Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
08/27
08/27
NCT04993755 / 2021-002251-11: A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Active, not recruiting
2a
42
Europe, US
TPN-101, 400 mg/day, Placebo
Transposon Therapeutics, Inc., Transposon Therapeutics, Inc
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
09/23
09/23
NCT05039099 / 2020-005971-11: A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Active, not recruiting
2
63
Europe, Canada, US, RoW
AP-101, Placebo
AL-S Pharma, AL-S Pharma
Amyotrophic Lateral Sclerosis
12/24
10/25
ReALiSe, NCT06441682: A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

Recruiting
2
60
Europe, Canada
ARGX-119, Placebo
argenx
Amyotrophic Lateral Sclerosis
07/27
07/27

Download Options